Brian McGee, engagement manager at Novasecta, weighs in on Bayer's proposed acquisition of agrochemical firm Monsanto. » Read More
The FDA approves two transcatheter heart valves manufactured by Edwards Lifesciences, CNBC's Seema Mody reports.
CNBC's Melissa Lee reports the latest on Valeant, including T. Row Price's lawsuit against the company.
Medivation briefly popped Wednesday after reports that at least five pharmaceutical companies expressed interest in buying it.
CSL CEO Paul Perreault talks to CNBC about the importance of smart acquisition strategies and a measured approach before expanding into new markets.
The hunt for yield has increased valuations for pharma stocks above their biotech counterparts, a rare feat that may present a buying opportunity.
This pediatrician can't believe that Congress would take a seven-week vacation at the height of mosquito season without approving Zika funding first.
Shares of Valeant Pharmaceuticals rose more than 6 percent after a Mizuho Securities analyst who had been bearish on the stock upgraded it.
CXRX shares plunged more than 27 percent after it posted quarterly earnings that missed estimates and replaced their CFO.
If you think more record highs are on the horizon for the Nasdaq, Deirdre Bosa breaks down the best historical ways to play it.
The investigations over the Philidor unit just add to Valeant's struggles to fix its broken business model, says Livermore Partners' David Neuhauser.
CNBC's Meg Tirrell reports the latest details on Valeant and its potential criminal probe. The "Fast Money Halftime Report" traders and Yana Barton, Eaton Vance portfolio manager, add perspective.
Valeant Pharmaceuticals shares fell more than 9 percent in pre-market trading after The Wall Street Journal reported the company is under federal investigation.
John Crowley, Amicus Therapeutics CEO, discusses the development of "orphan drugs" for patients with rare diseases. What I know personally and professionally is if we make great medicines, we'll not only change people lives, we'll build great businesses, says Crowley.
CNBC's Meg Tirrell takes a look at the difficult market for drugs that treat rare diseases.
Valeant Pharmaceuticals fortunes were discussed at a private shareholder dinner attended by top investor and board member William Ackman.
CNBC's Meg Tirrell reports on comments from Valeant CEO Joe Papa following the company's earnings release.
Get the best of CNBC in your inbox